Sandoz Group Ltd (SDZXF) Price & Analysis

Compare

12 Followers

SDZXF Stock Chart & Stats

$78.88

$0.00(0.00%)

At close: Jan 06 4:00 PM EST

$78.88

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$35.35 - $94.55

Previous CloseN/A

Volume50.00

Average Volume (3M)65.00

Market Cap

$34.52B

Enterprise Value$37.87B

Total Cash (Recent Filing)$1.74B

Total Debt (Recent Filing)$5.68B

Price to Earnings (P/E)32.9

Beta0.54

Next Earnings

Aug 06, 2026

EPS Estimate

1.99

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.87

Shares Outstanding440,000,000

10 Day Avg. Volume115

30 Day Avg. Volume65

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)3.35

Price to Sales (P/S)2.71

P/FCF Ratio38.83

Enterprise Value/Market Cap1.10

Enterprise Value/Revenue3.39

Enterprise Value/Gross Profit7.18

Enterprise Value/Ebitda23.22

Forecast

1Y Price Target

$88.45

Price Target Upside12.13% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)5.1

Revenue Forecast (FY)$15.29B

Bulls Say, Bears Say

Bulls Say

Revenue & Profitability ReboundA clear 2025 recovery (revenue up ~25%, net margin ~8%) signals stronger commercial execution and portfolio momentum. This rebound improves the firm's ability to fund operations and investments, supporting sustainable earnings generation over the next 2–6 months if execution and market access hold.

Consistent Gross MarginsStable gross margins near the mid‑40s reflect durable manufacturing scale and favorable product economics across generics and biosimilars. Persistent gross profitability provides structural buffer vs. pricing cycles and supports long‑run operating margin resilience.

Improved Cash GenerationMaterial FCF improvement to ~0.81B and OCF ~1.6B enhances financial flexibility to service debt, invest in capacity or biosimilars commercialization, and return value. Stronger cash conversion increases resilience against cyclical pressure and funds strategic initiatives.

Bears Say

Earnings And Cash Flow VolatilityMulti‑year swings in net income and FCF reduce forecasting reliability and hinder sustained capital allocation planning. Volatility suggests sensitivity to tender timing, launch competition and working capital cycles, complicating long‑term investment and stakeholder confidence.

Rising Absolute Debt & Data OutlierIncreasing absolute debt raises leverage and interest‑service risk, limiting strategic flexibility. The 2022 balance‑sheet outlier undermines confidence in trend assessment, making it harder to judge sustainable capital structure and credit resilience over the medium term.

Tender/Price Competition ExposureHeavy reliance on tender and institutional channels exposes margins to competitive price erosion and procurement cycles. Structural commoditization in generics means market share is price‑sensitive, requiring continual scale, cost control and successful biosimilar uptake to preserve long‑term profitability.

Sandoz Group Ltd News

Sandoz price target raised to CHF 62 from CHF 55 at Berenberg

Berenberg raised the firm’s price target on Sandoz (SDZNY) to CHF 62 from CHF 55 and keeps a...

11d ago

Sandoz downgraded to Hold from Buy at Deutsche Bank

Deutsche Bank downgraded Sandoz (SDZNY) to Hold from Buy with a CHF 70 price target Published first on...

18d ago

Sandoz downgraded to Equal Weight from Overweight at Barclays

Barclays downgraded Sandoz (SDZNY) to Equal Weight from Overweight with a price target of CHF 75, up from...

18d ago

Sandoz confirms E.C. granted marketing authorization for Ranluspec

Sandoz (SDZNY) confirmed that the European Commission, E.C., has granted marketing authorization for Ranluspec. Ranluspec is developed, manufactured...

21d ago

Sandoz receives U.S. FDA approval to expand Enzeevu label

Sandoz (SDZNY) announced that the US Food and Drug Administration, FDA, has approved an expanded label for Enzeevu,...

26d ago

Sandoz Raises CHF 550 Million in Bonds and Extends USD 2 Billion Credit Line

An update from Sandoz Group Ltd ( ($CH:SDZ) ) is now available. Sandoz has raised CHF 550 million...

5d ago

Sandoz reshapes biosimilar and generics leadership to seize upcoming patent cliff

The latest update is out from Sandoz Group Ltd ( ($CH:SDZ) ). Sandoz is restructuring to sharpen its...

6d ago

Sandoz lifts profit, dividend and 2026 outlook on biosimilar-driven growth

Sandoz Group Ltd ( ($CH:SDZ) ) has issued an update. Sandoz reported strong full-year 2025 results, with net...

19d ago

Sandoz wins EU approval for Ranluspec biosimilar, bolstering ophthalmology push

Sandoz Group Ltd ( ($CH:SDZ) ) has shared an update. Sandoz has secured European Commission marketing authorization for...

21d ago

Sandoz Wins Expanded U.S. FDA Label for Enzeevu Retinal Biosimilar

Sandoz Group Ltd ( ($CH:SDZ) ) has shared an announcement. Sandoz has secured U.S. FDA approval to expand...

26d ago

Sandoz upgraded to Buy from Hold at Jefferies

Jefferies analyst James Vane-Tempest upgraded Sandoz (SDZNY) to Buy from Hold with a price target of CHF 75,...

1M ago

Sandoz price target raised to CHF 63 from CHF 60 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Sandoz (SDZNY) to CHF 63 from CHF 60 and keeps...

2M ago

Sandoz price target raised to CHF 55 from CHF 49 at Berenberg

Berenberg raised the firm’s price target on Sandoz (SDZNY) to CHF 55 from CHF 49 and keeps a...

2M ago

Sandoz price target raised to CHF 63 from CHF 60 at Deutsche Bank

Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Sandoz (SDZNY) to CHF 63 from CHF...

2M ago

SDZXF FAQ

What was Sandoz Group Ltd’s price range in the past 12 months?

Sandoz Group Ltd lowest stock price was $35.35 and its highest was $94.55 in the past 12 months.

What is Sandoz Group Ltd’s market cap?

Sandoz Group Ltd’s market cap is $34.52B.

When is Sandoz Group Ltd’s upcoming earnings report date?

Sandoz Group Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 143 days.

How were Sandoz Group Ltd’s earnings last quarter?

Sandoz Group Ltd released its earnings results on Feb 25, 2026. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.73 by $0.14.

Is Sandoz Group Ltd overvalued?

According to Wall Street analysts Sandoz Group Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sandoz Group Ltd pay dividends?

Sandoz Group Ltd does not currently pay dividends.

What is Sandoz Group Ltd’s EPS estimate?

Sandoz Group Ltd’s EPS estimate is 1.99.

How many shares outstanding does Sandoz Group Ltd have?

Sandoz Group Ltd has 440,000,000 shares outstanding.

What happened to Sandoz Group Ltd’s price movement after its last earnings report?

Sandoz Group Ltd reported an EPS of $1.87 in its last earnings report, beating expectations of $1.73. Following the earnings report the stock price went up 14.329%.

Which hedge fund is a major shareholder of Sandoz Group Ltd?

Currently, no hedge funds are holding shares in SDZXF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sandoz Group Ltd

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.

Sandoz Group Ltd (SDZXF) Earnings & Revenues

Historic Earnings Reports

SDZXF Company Deck

SDZXF Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed picture with strong sales growth, particularly in the biosimilars segment and North American market recovery. However, the financial performance was impacted by negative free cash flow, a decline in core EBITDA margin, significant restructuring, and legal costs.View all SDZXF earnings summaries

SDZXF Stock 12 Month Forecast

Average Price Target

$88.45

▲(12.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"$39","102":"$102","54.75":"$54.8","70.5":"$70.5","86.25":"$86.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":101.32288,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$101.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$88.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.192552,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$72.19</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,54.75,70.5,86.25,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.38,88.45252923076923,89.52505846153846,90.59758769230768,91.67011692307692,92.74264615384615,93.81517538461539,94.8877046153846,95.96023384615384,97.03276307692308,98.10529230769231,99.17782153846153,100.25035076923076,{"y":101.32288,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.38,87.46230769230769,87.54461538461538,87.62692307692308,87.70923076923077,87.79153846153847,87.87384615384616,87.95615384615384,88.03846153846153,88.12076923076923,88.20307692307692,88.28538461538461,88.36769230769231,{"y":88.45,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.38,86.21173476923076,85.04346953846154,83.8752043076923,82.70693907692308,81.53867384615384,80.37040861538462,79.20214338461538,78.03387815384616,76.86561292307692,75.6973476923077,74.52908246153847,73.36081723076924,{"y":72.192552,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.98,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.45,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.425,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 54, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 56, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >